Peptides for healing tendons: what the BPC-157 tendon studies show, and what lifters report

Ask about peptides for healing tendons and the name that comes up first is BPC-157. The pitch is simple and confident: as the U.S. Anti-Doping Agency notes, some websites advertise it for “bone and joint healing, musculoskeletal injury repair” and more, claims the agency calls unproven (USADA). This page takes that pitch apart one study at a time. It puts the key tendon experiments in a single table, explains why there is still no published controlled trial of BPC-157 for tendons in people, covers the side-effect questions, and sets all of it next to what injured lifters actually report. The short version: the rat data are genuinely interesting, and the human data barely exist.

Do peptides help heal tendons?

No peptide has been shown to heal a tendon in a controlled human trial. The peptide most often discussed for it is BPC-157, and its tendon record is almost entirely in rats, where it repeatedly improved healing on strength, function and microscope measures. The most recent review of the human record counted three small published studies, none of them a controlled tendon trial, and concluded that “until well-designed human trials are conducted and published, BPC-157 should not be recommended for clinical use in musculoskeletal medicine” (McGuire et al., 2025). So the honest answer to “does BPC-157 work for tendons” is: in rats, consistently; in people, unknown.

That gap matters more for tendons than for most tissues. Tendons and ligaments are hypovascular and hypocellular, meaning poor blood supply and few resident cells, which is why reviewers writing in Cell and Tissue Research singled them out as the tissues where BPC-157 “has promise as a therapy to conservatively treat or aid recovery” (Gwyer et al., 2019). Slow-healing tissue is exactly where people are most tempted to reach for something, and exactly where a placebo effect or ordinary healing over time is easiest to mistake for a drug working.

What is BPC-157, and why do lifters use it for tendons?

BPC-157 is a synthetic peptide of 15 amino acids, short for “body protection compound”, derived from a sequence originally found in human gastric juice. It is not a hormone or a steroid. It is an experimental compound that has never completed the large human trials a medicine goes through. The 2019 Cell and Tissue Research review that surveyed the field framed the question plainly: is BPC-157 “a feasible therapy for healing and functional restoration of soft tissue damage, with a focus on tendon, ligament and skeletal muscle healing” (Gwyer et al., 2019)?

The people asking about it are mostly lifters and weekend athletes with a slow tendon problem: an Achilles, a patellar tendon, an elbow, a shoulder. In our snapshot of public posts on X it was framed mainly as a tissue-repair and injury-recovery peptide, often paired with TB-500. For how it fits into the wider recovery category, see our overview of peptides for injury recovery.

What did the rat tendon studies show?

The BPC-157 tendon literature is a set of controlled rat experiments, mostly from one research group in Zagreb, plus cell-culture work from a group in Taiwan. Across the Zagreb healing studies, treated rats healed better than untreated controls on hard biomechanical measures (how much load the tendon took before failing, how stiff it was), on walking function, and under the microscope; one study looked only at blood-vessel markers. A 2026 study from a separate group in Turkey, on surgically repaired Achilles tendons, was more mixed for BPC-157 alone. The table below lists the key studies, what injury they modeled, and what was measured.

A few details stand out. In the 2006 Achilles study, the authors chose an injury that, in their words, “could not be healed spontaneously”, and BPC-157 given alone, without any carrier, recovered it (Krivic et al., 2006). The corticosteroid result is worth knowing if you are weighing a peptide against a cortisone shot; our comparison of peptides versus cortisone for injury covers that question. It is still a rat finding.

The honest reading of the table: the direction of the results is remarkably consistent, with the 2026 repaired-tendon study the softest result, the measures are objective, and the injuries are severe. What the table also shows is that every row is a rat or a dish. Gwyer and colleagues add a caution that is easy to miss: “over the past two decades, only a handful of research groups have performed in-depth studies regarding this peptide” (Gwyer et al., 2019).

Do peptides help heal joints and ligaments?

For ligaments, the evidence looks like the tendon evidence: positive, and in rats. In the MCL study, BPC-157 produced “consistent functional, biomechanical, macroscopic and histological healing improvements” over 90 days, whether it was injected, added to drinking water or rubbed on as a cream (Cerovecki et al., 2010). That the route seemed not to matter in rats is part of why oral capsules became popular, though whether a capsule and an injection behave the same way in people is untested; our explainer on BPC-157 oral versus injection goes through that question.

For joints, the only human data point is a small knee study. A clinic in Florida reviewed the charts of patients who had received a BPC-157 injection into the knee, alone or with thymosin beta-4, and phoned them 6 months to a year later: 14 of the 16 reached said their knee pain had improved significantly (Lee and Padgett, 2021). The patients had a mix of diagnoses, there was no control group, and no standard tool was used to measure function or stiffness. The 2025 review flags the same weaknesses: a small sample, no control group and no common diagnosis (McGuire et al., 2025). It is a reason to run a trial, not a result.

How might BPC-157 work on tendon tissue?

The leading explanation is that BPC-157 helps an injury site grow new blood vessels and helps repair cells survive and move, which would matter most in poorly supplied tissue like tendon. Reviewers describe it as increasing VEGFR2 activity and nitric-oxide signaling through the Akt-eNOS pathway, activating ERK1/2 signaling, and lowering inflammatory signals such as TNF-alpha and IL-6 (McGuire et al., 2025). In tendon tissue specifically, the lab work points to three things: faster migration and survival of tendon cells through FAK-paxillin signaling (Chang et al., 2011), more growth hormone receptors on those cells (Chang et al., 2014), and blood-vessel growth that was adjusted to the healing tissue rather than switched on everywhere (Brcic et al., 2009).

One puzzle runs through all of it. BPC-157 has “a very short half-life (less than 30 min)”, yet in animals the processes it starts “appear to persist for weeks to months” (McGuire et al., 2025). How a compound that is gone in half an hour produces months of effect is not understood. Every mechanism in this section is a working hypothesis from animal and cell data, not an account of what happens in a human tendon.

Does BPC-157 work in humans?

Nobody knows yet, because the human evidence is three small studies, and none tested a tendon injury. The 2025 review in Current Reviews in Musculoskeletal Medicine found that “there have only been three published studies” in people: the 16-patient knee chart review above, a 12-patient pilot of bladder injections for interstitial cystitis, and an infusion safety study in 2 healthy adults (McGuire et al., 2025). That is a few dozen people across unrelated conditions. The reviewers also flagged that “all the published studies report positive or beneficial effects”, which they said suggests “a possible publication bias toward positive findings.” For a wider view, PeptideAgent’s review of peptides for tendon repair grades BPC-157, TB-500 and GHK-Cu for this use, finds animal-only evidence at best, and sets each one against the standard of care of progressive loading and physical therapy.

The table below sets the animal record next to the human one.

BPC-157 for tendon and soft-tissue recovery: what animal and cell studies show versus what human evidence supports, as of October 2026. ’Preclinical’ means rats or cultured cells; it does not establish an effect in people.

Attribute	Animal / preclinical evidence	Human evidence
Tendon healing (Achilles cut or detached)	Stronger, better-functioning tendons in several rat studies	No published controlled trial
Ligament (MCL) healing	Consistent improvements in rats across three routes	No published controlled trial
Muscle-tendon junction	Full functional recovery and less muscle wasting in a rat defect model	No published controlled trial
Joint pain	Not the focus of the animal tendon work	One uncontrolled chart review of 16 knee patients
Proposed mechanism	Blood-vessel growth, cell survival and migration, growth hormone receptors	Not characterized in humans
Published studies	Many, over about 20 years, from a handful of groups	Three, all small
Randomized controlled trials	Numerous controlled animal experiments	None published

Why is there still no human trial of BPC-157 for tendons?

There is still no published one, but that is starting to change. Reviewers point to a narrow research base, with only “a handful of research groups” doing in-depth work over two decades (Gwyer et al., 2019), and the 2025 review said the absence of high-quality human trials “limits the ability to assess its human safety, efficacy, and appropriate clinical use,” adding that the peptide’s continued availability on “research chemical” websites and its anecdotal promotion on social media “only heighten the urgency for rigorous scientific investigation” (McGuire et al., 2025).

The public trial registry now lists two placebo-controlled injury trials, one of them on tendon repair, alongside an older safety study. None has reported results.

The two injury trials measure what lifters actually care about. The hamstring study’s co-primary endpoints are time to return to unrestricted sport and change in MRI-measured injury volume, with both groups following the same rehab program. The rotator cuff pilot will look at tendon healing on MRI, strength, range of motion and patient-reported outcomes; its own summary describes BPC-157 as a peptide that “has not yet been studied in formal human clinical trials.” Until those results are published, the human answer stays open.

How long does BPC-157 take to work for a tendon?

There is no human answer, because no trial has measured it. What exists is the length of the animal experiments: rat tendon and ligament studies observed healing over windows from 14 days (Staresinic et al., 2003) and 21 days (Krivic et al., 2006) to 42 days (Japjec et al., 2021) and 90 days (Cerovecki et al., 2010). Those are study designs, not a schedule for a human Achilles. Our page on how long BPC-157 takes to work goes into why forum timelines do not hold up.

What are the side effects and safety unknowns?

The most accurate statement about BPC-157’s human safety is that it has barely been measured. One preclinical evaluation could not identify a minimum toxic dose or a lethal dose in animals (McGuire et al., 2025), but a clean record in rodents is not a safety profile in people. The U.S. Anti-Doping Agency puts it directly: because BPC-157 “has not been extensively studied in humans, it is unknown if there is a safe dose, or if there is any way to use this substance safely to treat any specific medical conditions” (USADA). The FDA has said compounded BPC-157 “may pose risk for immunogenicity for certain routes of administration” and that it has “no, or only limited, safety-related information” for the proposed routes (FDA).

What the three small human studies recorded is reassuring as far as it goes. The bladder pilot screened for fever, rash, nausea, vomiting and worsening urinary symptoms and reported none; the knee series reported no adverse effects but did not describe how it looked for them; and the two-person infusion study saw no changes in vital signs, heart tracings or blood markers of liver, kidney, thyroid or metabolic function (McGuire et al., 2025). The same review lists theoretical risks drawn from how the peptide behaves in cells: abnormal blood-vessel growth of the kind tumors rely on, toxic metabolites, and an overactive nitric-oxide system, which at high levels is linked to anemia and altered drug metabolism. It also notes evidence pointing the other way, including studies where BPC-157 counteracted tumor-driven blood-vessel signaling. These are open questions, not observed harms. Our BPC-157 side effects guide covers them in more depth.

The second risk is what is in the vial. Much of the BPC-157 sold online is “research use only” product whose contents nobody independently checks. When an anti-doping lab analyzed 337 black-market performance products, it found a wide range of substances, including peptide hormones and growth factors, the SARM LGD-4033 and a fusion protein of unknown activity (Krug et al., 2014). A Belgian study of the ten peptide drugs most often found falsified on its market, bought from suspected illegal internet pharmacies, reported purity as low as 5 percent for some peptides, arsenic above toxicity limits in several samples and lead in one (Janvier et al., 2018). BPC-157 was not singled out in those studies, but they show what an unregulated peptide supply can hold.

BPC-157 alone or with TB-500 for tendons?

There is no controlled comparison in people, and only one in rats. In a 2026 study, 32 rats had their Achilles tendons cut and surgically repaired, then received a control, BPC-157, TB-500 or both for four weeks (Biçer et al., 2026). TB-500 alone was the only group with a statistically significant gain in the load the tendon could take before failing; BPC-157 alone scored better than controls numerically on tissue scores, but its total scores did not reach significance. The authors reported that “combined BPC-157 and TB-500 treatment did not confer additional benefits compared to either agent alone,” and called the work exploratory.

The only human data point that splits the two is the small knee chart review, and it is far too small to rank anything.

Source: Lee and Padgett, 2021, a retrospective phone survey with no control group. With four people in one arm, the difference between the rows means nothing. Taken together with the rat study, pairing the two is a community practice, not an evidence-based protocol. For why people stack them anyway, see our explainers on the Wolverine stack and on BPC-157 and TB-500 together.

What are injured lifters saying about BPC-157?

Online, BPC-157 is talked about as an injury and tissue-repair peptide, and the talk runs well ahead of the studies above. Our snapshot of 16 public posts on X about BPC-157 for recovery, collected in July 2026, found people framing it mainly as a compound for tissue repair, including one user describing use alongside TB-500 after a fracture and surgical repair. Sentiment was mixed: roughly 45 percent of the posts read as positive and the rest as negative, mixed or skeptical, a non-scientific reading of a small sample.

Safety was the sharpest split. One poster said they had compiled self-reported adverse events, flagged a possible cancer signal and tied it to the peptide’s effect on blood-vessel (VEGF) signaling, while cautioning that nobody knows how many people use it; another insisted it is cheap and very safe. Neither side is evidence, but the argument tracks the theoretical blood-vessel question the 2025 review raises. The bigger problem with tendon testimonials is built in. Soft-tissue healing normally runs through an inflammatory phase in the first days, a repair phase over roughly the first two weeks, and a remodeling phase that lasts from about day 14 to 90 days or more (McGuire et al., 2025). A tendon that feels better a few weeks into a peptide may simply be on that normal curve, and a post rarely says what else changed or what was really in the vial.

If you compete in a tested sport, BPC-157 is prohibited under WADA’s S0 Non-Approved Substances category (USADA); our explainer on recovery peptides and athletes covers what that means.

What this means if tendon recovery is your goal

If you want a stubborn tendon or ligament to settle, the useful move is to take the goal, not the compound, to a licensed provider who can weigh what has evidence for your specific injury. As this page has shown, the BPC-157 tendon evidence is consistent in rats and nearly absent in people, its human safety record is a few dozen participants, and the first controlled human injury trials are only now registered, with one recruiting. A provider can set those facts next to the rest of your options, from structured rehab and load management to treatments with a larger evidence base, and help you decide based on your injury rather than on a forum thread.

BPC-157 status: Not FDA-approved; sold by some telehealth providers as a compounded prescription. An FDA advisory committee reportedly voted in July 2026 to recommend allowing pharmacies to compound it; nothing has changed yet. How peptide status works.

Educational information only, not medical advice. Scientific statements are sourced to the peer-reviewed literature, ClinicalTrials.gov records and the USADA and FDA documents linked above, checked as of October 12, 2026. This page is drafted with AI assistance and fact-checked against the cited primary sources before publication.